<abstract xmlns="http://www.w3.org/1999/xhtml"> INTRODUCTION: Sarcomas are a rare and heterogeneous group of tumours of mesenchymal origin. Single agent pazopanib showed activity in a phase II clinical trial designed to screen various soft tissue sarcoma subtypes [10] and a phase III [11] clinical trial followed resulting in FDA approval in 2012 for use in metastatic soft tissue sarcoma exposed to prior chemotherapy. METHODS: We conducted an independent computerised review of PubMed and ScienceDirect database up to May 2015 using combinations of terms such as soft tissue sarcoma, pazopanib, STS ,VEGFR2, TKIs ,angiogenesis, advanced sarcoma treatment, targeted therapy for sarcoma AIM: Our aim was to explore the role of pazopanib in soft tissue sarcoma (STS) treatment, its mode of action, the clinical trials supporting its approval, safety and efficacy, how the product fits into the real world and its contribution to the development of targeted therapy for STS CONCLUSION: Pazopanib is a valid, innovative and cost-effective approach in the treatment of advanced pre-treated STS</abstract>

INTRODUCTION: Sarcomas are a rare and heterogeneous group of tumours of mesenchymal origin. Single agent pazopanib showed activity in a phase II clinical trial designed to screen various soft tissue sarcoma subtypes [10] and a phase III [11] clinical trial followed resulting in FDA approval in 2012 for use in metastatic soft tissue sarcoma exposed to prior chemotherapy. METHODS: We conducted an independent computerised review of PubMed and ScienceDirect database up to May 2015 using combinations of terms such as soft tissue sarcoma, pazopanib, STS ,VEGFR2, TKIs ,angiogenesis, advanced sarcoma treatment, targeted therapy for sarcoma AIM: Our aim was to explore the role of pazopanib in soft tissue sarcoma (STS) treatment, its mode of action, the clinical trials supporting its approval, safety and efficacy, how the product fits into the real world and its contribution to the development of targeted therapy for STS CONCLUSION: Pazopanib is a valid, innovative and cost-effective approach in the treatment of advanced pre-treated STS

The role of Pazopanib in Soft Tissue Sarcoma: A comprehensive review of the literature

Oncology Unit, Third Department of Medicine, University of Athens, Athens, Greece

Department of Medical Oncology, Ioannina University Hospital, Greece

Forum of Clinical Oncology

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

INTRODUCTION: Sarcomas are a rare and heterogeneous group of tumours of mesenchymal origin. Single agent pazopanib showed activity in a phase II clinical trial...

The role of Pazopanib in Soft Tissue Sarcoma: A comprehensive review of the literature

Publié en ligne: 17 déc. 2015

Pages: 13 - 21

DOI: https://doi.org/10.1515/fco-2015-0012

Mots clés
Soft tissue sarcoma, Pazopanib, STS, VEGFR2, TKIs, Angiogenesis, Advanced sarcoma treatment, Targetted therapy for sarcoma

© 2015

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

The role of Pazopanib in Soft Tissue Sarcoma: A comprehensive review of the literature

Publié en ligne: 17 déc. 2015

Pages: 13 - 21

DOI: https://doi.org/10.1515/fco-2015-0012

Mots clésSoft tissue sarcoma, Pazopanib, STS, VEGFR2, TKIs, Angiogenesis, Advanced sarcoma treatment, Targetted therapy for sarcoma

© 2015

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Mots clés
Soft tissue sarcoma, Pazopanib, STS, VEGFR2, TKIs, Angiogenesis, Advanced sarcoma treatment, Targetted therapy for sarcoma